Compare · MRNA vs PFE
MRNA vs PFE
Side-by-side comparison of Moderna Inc. (MRNA) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. MRNA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while PFE focuses on Biotechnology: Pharmaceutical Preparations.
- PFE is the larger of the two at $158.11B, about 2.3x MRNA ($69.04B).
- Over the past year, MRNA is up 551.0% and PFE is up 15.4% - MRNA leads by 535.6 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 6 for PFE).
- Both have 25 recent analyst ratings on file.
- Company
- Moderna Inc.
- Pfizer Inc.
- Price
- $172.83+12.23%
- $27.75+0.54%
- Market cap
- $69.04B
- $158.11B
- 1M return
- +29.72%
- -0.25%
- 1Y return
- +550.96%
- +15.41%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest MRNA
- Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
- President Hoge Stephen exercised 152,905 shares at a strike of $12.21 and sold $11,691,420 worth of shares (80,575 units at $145.10) as part of a pre-agreed trading plan, increasing direct ownership by 5% to 1,562,029 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Mock James M exercised 19,836 shares at a strike of $30.96 and sold $4,685,094 worth of shares (34,836 units at $134.49) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 59,375 units (SEC Form 4)
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
Latest PFE
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- SEC Form N-PX filed by Pfizer Inc.
- New insider Guegan Cecile claimed ownership of 149,505 shares (SEC Form 3)
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency